IL1B and lung carcinoma: The incidental finding from the CANTOS trial, where IL-1β inhibition with canakinumab reduced lung cancer incidence and mortality, prompted the CANOPY trials, which evaluated IL-1β blockade in NSCLC [24,26,33,34,35].